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Abstract
Background: Due to their nanometric scale (50 nm) along with their biomimetic properties, lipid nanocapsules loaded with
Rhenium-188 (LNC
188Re-SSS) constitute a promising radiopharmaceutical carrier for hepatocellular carcinoma treatment as
its size may improve tumor penetration in comparison with microspheres devices. This study was conducted to confirm the
feasibility and to assess the efficacy of internal radiation with LNC
188Re-SSS in a chemically induced hepatocellular
carcinoma rat model.
Methodology/Principal Findings: Animals were treated with an injection of LNC
188Re-SSS (80 MBq or 120 MBq). The
treated animals (80 MBq, n=12; 120 MBq, n=11) were compared with sham (n=12), blank LNC (n=7) and
188Re-
perrhenate (n=4) animals. The evaluation criteria included rat survival, tumor volume assessment, and vascular endothelial
growth factor quantification. Following treatment with LNC
188Re-SSS (80 MBq) therapeutic efficiency was demonstrated by
an increase in the median survival from 54 to 107% compared with control groups with up to 7 long-term survivors in the
LNC
188Re-SSS group. Decreased vascular endothelial growth factor expression in the treated rats could indicate alterations
in the angiogenesis process.
Conclusions/Significance: Overall, these results demonstrate that internal radiation with LNC
188Re-SSS is a promising new
strategy for hepatocellular carcinoma treatment.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
malignant tumor worldwide. The prognosis of HCC remains
extremely poor, and a curative treatment (liver transplantation,
surgical resection, and radiofrequency ablation) can only be
carried out in approximately 25% to 30% of cases [1]. The use of
conventional external beam radiation therapy in HCC treatment
has been limited by the low radiation tolerance of the cirrhotic
liver that often resulted in radiation-induced liver disease (RILD)
[2]. Selective internal radiotherapy (SIRT) aims to deliver high
tumoricidal doses while limiting the development of RILD. This
locoregional strategy is defined as the infusion of radioactive
carrier including microsphere of Yttrium-90, Iodine-131 iodized
oil or similar agent into the hepatic artery [3]. Currently,
90Y-
microspheres are the most SIRT technique used. Given the
hypervascularity of HCC,
90Y-microspheres injected into the
hepatic artery will spread throughout the liver or confined to
certain areas, where they can stop blood supply of the tumor by
the embolisation process.
Progress in pharmaceutical research field has been exploited in
the design of tumor-targeting nanoscale vectors able to deliver
radionuclides. Among them, lipid nanocapsules (LNC), a nano-
vector with biomimetic properties [4], appear to be a useful
therapeutic option for HCC treatment. Composed of a liquid
lipidic core surrounded by a tensioactive shell, LNC lead to the
encapsulation of a lipophilic complex of Rhenium-188
(c=155 keV; b
-=2 MeV; T1/2=16.9 h). The formulation, based
on a fully automated phase-inversion process, is simple and results
in nanoparticles solution presenting a mean diameter between 20
and 100 nm, depending on the quantity of excipients. The
nanometric scale of LNC
188Re-SSS (50 nm) could be highly
advantageous, as LNCs may penetrate more deeply inside the
tumor blood vessels, the mean diameter of microsphere devices are
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e16926varying between 20 to 500 mm. Moreover, enhanced permeability
retention effect (EPR), the main strategy for the delivery of
nanoparticulate systems, may improve therapeutic efficiency.
Indeed, it has been shown that small particles can passively cross
the sinusoidal endothelium of the liver through fenestrations with a
size of approximately a few hundred nanometers [5,6].
We report a study of LNC
188Re-SSS as a new radiopharma-
ceutical carrier for internal radiotherapy of rats presenting
hepatocellular carcinoma induced by diethylnitrosamine. No early
mortality and no intolerance following LNC
188Re-SSS intra-
arterial injection were observed. Our results provide evidences of
therapeutic efficiency of LNC
188Re-SSS with a reduction in tumor
progression which could be combinated with an altered angio-
genesis process as indicated by VEGF quantifications in plasmatic
samples in a rat HCC model.
Methods
Ethics Statement
This study was carried out in strict accordance with the French
Minister of Agriculture and the European Communities Council
Directive of 24 November 1986 (86/609/EEC). The protocol was
approved by the Committee on the Ethics of Animal Experiments
of the ‘‘Pays de la Loire’’ (Permit Number: CEEA.2009.6). All
surgery was performed under ketamine/xylazine anesthesia, and
all efforts were made to minimize suffering.
Materials
Lipoı ¨dH S75-3 (soybean lecithin with 69% of phosphatidylcho-
line) and SolutolH HS15 (a mixture of polyethylene glycol 660 and
polyethylene glycol 660 hydroxystearate) were kindly donated by
Lipoı ¨d Gmbh. (Ludwigshafen, Germany) and BASF (Ludwigsha-
fen, Germany), respectively. NaCl and dichloromethane were
provided by Sigma (St-Quentin, Fallavier, France). Deionized
water was obtained from a Milli-Q plus system (Millipore, Paris,
France). Lipophilic LabrafacH CC (caprylic-capric acid triglycer-
ides) was provided by Gattefosse S.A. (Saint-Priest, France).
Preparation of the
188Re-SSS complex
188Re as carrier-free Na [
188ReO4
-] in a physiological solution
was obtained by saline elution of a
188W/
188Re generator (Institut
des Radioe ´le ´ments [Institute for Radioelements], Fleurus, Belgium)
and then concentrated. The
188Re-SSS complex was prepared
according to the method developed by Lepareur et al.[7]. In brief,
the
188Re-SSS complex was obtained by the reaction of the ligand
sodium dithiobenzoate (organic synthesis platform, Rennes,
France) with a freeze-dried formulation kit containing 30 mg
sodium gluconate, 30 mg ascorbic acid, 40 mg potassium oxalate,
and 4 mg SnCl2.2H2O reconstituted in 0.5 mL of physiological
serum. 1 110 MBq of
188Re-perrhenate (
188ReO4
-, in 0.5 mL) was
added, and the solution was mixed for 15 minutes at room
temperature. Then, 20 mg of sodium dithiobenzoate (in 0.5 mL;
pH=7) was added before being heated at 100uC for 30 minutes,
which allowed for the formation of the
188Re-SSS complex. Due to
its precipitation in aqueous media, the
188Re-SSS complex was
extracted with dichloromethane (1 mL) and washed three times
with 1 mL of deionized water. The radiochemical purity (RCP) of
the complex was checked by thin-layer chromatography as the
ratio of migrated radioactivity to total radioactivity. Thin-layer
chromatography was carried out using silica gel 60-F254 alumina
plates (Merck) and a solution of petroleum ether/dichloromethane
(6/4; v/v) as an eluant. Radioactivity was assessed with a
phosphor-imaging machine (Packard, Cyclone storage phosphor
system).
Nanocapsule formulation and characterization
The overall study was performed on 50 nm-diameter LNCs
which were prepared according to a phase-inversion process
described by Heurtault et al. [4]. In brief, 25 mg Lipoı ¨d H S75-3,
282 mg SolutolH HS15, 342.7 mg LabrafacH, 29.7 mg NaCl, and
987.5 mg deionized water were mixed by magnetic stirring. The
188Re-SSS complex extracted with dichloromethane (1 mL) was
then added to the other components of the emulsion. The organic
solvent was removed by being heated at 60uC for 15 minutes.
Three cycles of progressive heating and cooling between 85uC and
60uC were then carried out and followed by an irreversible shock,
induced by dilution with 4.16 mL of 0uC deionized water, which
was added to the mixture at 70uC leading to 50 nm-lipid
nanocapsules solution. Afterwards, slow magnetic stirring was
applied to the suspension for 5 minutes. LNC
188Re-SSS were
dialyzed during 2 hours with deionized water at room temperature
by magnetic stirring. The mean diameter and polydispersity index
were then determined using a Malvern ZetasizerH Nano Serie
DTS 1060 (Malvern Instruments S.A., Worcestershire, UK). The
encapsulation yield was assessed with a gamma counter (Packard
Auto-Gamma 5,000 series) according to the equation below.
Encapsulation yield % ðÞ :
~ LNC188Re{SSS activity after dialysis

LNC188Re-SSS activity before dialysis
 
|100
HCC model and treatment
49 Male Wistar rats weighting 150–180 g were obtained from
the animal house of the Angers University Hospital. The animals
were kept in polycarbonate cages in a room with controlled
temperature (20–22uC), humidity (50–70%), and light (12-hour
light/dark cycles). Room air was renewed at the rate of 10 vol/
hour. Tap water and food were provided ad libitum.
All experiments were performed on 6-week-old male Wistar
rats. Hepatic carcinogenesis was induced chemically by adding
diethylnitrosamine (DENA) to drinking water (100 mg/L) for 8
weeks. Each animal underwent hepatic artery catheterization on
Day 10 (D10) after the end of tumor induction. Two LNC
188Re-
SSS groups were performed with one intra-hepatic artery
injection of 80 MBq and 120 MBq of LNC
188Re-SSS
(LNC
188Re-SSS – 80 MBq, n=12; LNC
188Re-SSS – 120 MBq,
n=11) as described in the ‘‘Hepatic artery catheterization’’
section below. Three control groups, the
188ReO4
- group
(80 MBq, n=4), the sham group (n=12) and the blank LNC
group (n=10) were assessed with the same procedure. We set the
therapeutic activity at 80 MBq and 120 MBq, corresponding to
an absorbed dose to the liver of 40Gy, which proved to be
effective in the treatment of human HCC [8], and of 65Gy in
order to appreciate the effect of a higher dose after LNC
188Re-
SSS internal radiation.
Hepatic artery catheterization
Hepatic artery catheterization was carried out according to
the Garin et al. method [9]. The experiment was continued
under a binocular magnifying glass. The first duodenal loop was
pulled down to expose the gastroduodenal artery which was,
after identification of the celiac and hepatic arteries, carefully
dissected. A final distal ligature of the gastroduodenal artery was
performed, and the celiac artery was clamped to temporarily
stop arterial flow. After perforation using a 30 G needle, a 32 G
catheter (CS-32, Bioseb, Vitrolles, France) was placed inside the
gastroduodenal artery, and a volume of 400 mLo fL N C
188Re-
SSS,
188ReO4
-, or blank LNC solution was then injected. After
LNC188Re-SSS Study on a Rat HCC Model
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the gastroduodenal artery was tied off and arterial flow was
restored. Concerning the sham group, the same procedure was
performed except the injection which was not realized and a
final ligature of the hepatic artery. This control group led to an
appreciation of the collateral revascularization which could
occur after injection.
Transaminase assessment
Blood samples were collected from the tail vein using
heparinized tubes in each group at D12, D18, D24, D25, D30,
D45, D55, D65, D80, D90, D105, D130, and D152 after the end
of tumor induction in order to assess hepatotoxicity after
treatment injection. After centrifugation at 1 000 g for 20
minutes, plasma alanine aminotransferase (ALT) and aspartate
aminotransferase [10] were assessed using BioMe ´rieux kits
(Marcy l’e ´toile, France) according to the manufacturer’s instruc-
tions.
Dosage of plasmatic vascular endothelium growth factor
(VEGF)
Blood samples were collected from the tail vein using
heparinized tubes in each group at D12, D20, D40, D55, D65,
D80, and D105 after the end of tumor induction. After
centrifugation at 1 000 g for 20 minutes, the rat VEGF ELISA
test (R&D Systems Europe, Lille, France) was immediately
performed according to the manufacturer’s instructions.
Magnetic resonance imaging
Six animals from the LNC
188Re-SSS – 80 MBq and four
animals from the
188Re-perrhenate groups were explored by MRI
in order to acquire images of the treatment-induced morpholog-
ical changes at day 100 after the end of tumor induction. MRI
was performed with a 1.5T Signa Excite HD device (General
Electric Medical System Milwaukee, Ilinois). Rapid T2-weighted
images were obtained using a fast spin echo (FSE) sequence with
the following parameters: TR=2500 s, TE=102 s, matrix
3206320, twelve slices, thickness 3 mm, gap 0.5 mm,
FOV=15 cm, Nex=4, acquisition time 69300). The following
day, the animals were sacrificed for macroscopic and histopath-
ological analyses.
Whole-body planar c-scintigraphy
Three animals from the LNC
188Re-SSS – 80 MBq and three
animals from the
188Re-perrhenate groups were explored by
whole-body planar c-scintigraphy. Static 15-minutes scintigraphy
acquisitions were obtained using a gamma camera (SOPHA DSX
c camera, 155 keV615%, 128
2 matrix, HRLE collimator).
188Re-perrhenate and LNC
188Re-SSS solutions (80 MBq) were
injected into the hepatic artery, and images were taken at 1.5 h,
3 h, and 24 h. A scan projection radiograph (Scout View) was
acquired on a GE lightspeed system (General Electric Medical
System Milwaukee, Ilinois) and fused with planar scintigraphy of
the same animal for the localization of
188ReO4
- and LNC
188Re-
SSS.
Tissue distribution study
A tissue distribution study was carried out on an extra group
of 24 male Wistar rats with chemically-induced HCC. They
were divided into two groups: one injected with a
188ReO4
-
solution following hepatic artery catheterization (n=12), and
the other with LNC
188Re-SSS – 80 MBq (n=12). In both
groups, the animals were sacrificed at 1.5 h (n=4), 3 h (n=4),
and 24 h (n=4) post-injection. The organs were removed,
washed, and weighed (blood, liver, spleen, kidneys, heart, lung,
stomach, small intestine, large intestine, bladder, bone, muscle,
brain, tail, and carcass). The content activity of each organ was
determined using a gamma counter (Packard Auto-Gamma
5,000 series).
Statistical analysis
The Kaplan-Meier method was carried out to plot animal
survival. Statistical significance was assessed using the log-rank test
(Mantel-Cox Test). StatView software was used for this purpose,
and the tests were considered significant at p values less than 0.05.
The different groups were compared in terms of survival time,
increase in median survival time (IMST %), maximal survival
time, and long-term survivors (rats were considered to be long-
term survivors if they survived twice the median survival time of
control groups [11]).
Results
Encapsulation of the
188Re-SSS complex in LNCs
The
188Re-SSS complex presents a good purity as satisfactory
RCP of more than 98% was obtained. Physico-chemical
characteristics of the LNC are provided in Table 1. Blank LNCs
were measured at 50.765.7 nm.
188Re-SSS entrapping did not
change the characteristics of nanoparticles with a size of
49.762.7 nm. Blank LNC and LNC
188Re-SSS solutions were
monodispersed with a polydispersity index of 0.05 (Table 1). The
encapsulation yield was approximately 97.9%, 97.7% and 97.5%
after 2 h, 24 h and 48 h of dialysis, against phosphate buffer
solution (pH=7.4), respectively; therefore,
188Re-SSS release of
2.5% observed at 48 h can be neglected.
Biodistribution study
Planar scintigraphy led to the monitoring of the radioactivity
distribution of LNC
188Re-SSS and
188ReO4
- following hepatic
artery injection (Figure 1a). Results highlighted a liver uptake
following LNC
188Re-SSS injections and a stomach uptake after
188ReO4
- injection up to 24 hours.
LNC
188Re-SSS were essentially confined to the liver, with an
increased uptake up to 24 h (1.5 h post-injection: 1.676
0.39%ID/g; 3 h post-injection: 2.9360.75%ID/g; 24 h post-
injection: 4.5160.72%ID/g) in correlation with an increased of
the blood clearance (1.5 h post-injection: 0.7960.16%ID/g; 3 h
Table 1. Physico-chemical characteristics of blank and
188Re-SSS LNCs.
Mean particle size Polydispersity index Encapsulation yield (%)
Blank LNC 50.765.7 0.0560.02 -
LNC
188Re-SSS 49.762.7 0.0560.03 97.960.2
doi:10.1371/journal.pone.0016926.t001
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0.01%ID/g).
Contrary, the tissue distribution study of
188Re-perrhenate
solution revealed a rapid stomach uptake (1.5 h post-injection:
3.2161.47%ID/g; 3 h post-injection: 4.5860.85%ID/g; 24 h
post-injection: 1.2860.51%ID/g).
Survival study
The descriptive and statistical data from the survival study are
summarized in Table 2.
As shown in Figure 2, all animals of the control groups died due
to tumor progression at D105, with a median survival time of
51619 days, 77619 days, and 57624 days for blank LNC, sham,
and
188ReO4
- groups, respectively. There was no significant
difference between the three control groups (p.0.05).
Following treatment with LNC
188Re-SSS (80 MBq) therapeutic
efficiency was demonstrated by an increase in the median survival
from 54 to 107% as compared to control groups with up to 7/12
long-term survivors in the LNC
188Re-SSS group (80 MBq). Even
if a slight difference in median survival time was observed between
LNC
188Re-SSS – 80 MBq (118627 days) and LNC
188Re-SSS –
120 MBq (97618 days), comparison with these two groups was
not significant (p=0.4431).
Tumor volume assessment was performed using two different
evaluation methods: MRI and macroscopic study. Figure 3 shows
MRI and macroscopic views of control groups (sham,
188ReO4
-
and blank LNC) and LNC
188Re-SSS – 80 MBq rats at D100
(MRI) and D101 (macroscopy) after the end of tumor induction.
Liver tumors represented approximately 100% of the liver
parenchyma for control rats, while they occupied only 50% of
the liver tissue for LNC
188Re-SSS – 80 MBq rats. Therefore, 50%
of healthy liver tissue appeared to be preserved following
LNC
188Re-SSS – 80 MBq treatment. This observation was
confirmed by histopathological analysis (data not shown).
Transaminases assessment
Transaminases were assessed in each group and compared to
healthy rat data. As shown in Tables 3 and 4, the AST and ALT
kinetics were very similar, with a slight liver toxicity starting at
D12 for the LNC
188Re-SSS– 80 MBq group (AST, LNC
188Re-
SSS – 80 MBq group: 104 UI/mL, sham group: 74 UI/mL,
188ReO4
- group: 87 UI/mL, blank LNC group: 84 UI/mL,
healthy rats: 76 UI/mL), which faded with normalization of
AST levels at D55 (LNC
188Re-SSS– 80 MBq: 80 UI/mL, sham
group: 95 UI/mL,
188ReO4
- group: 106 UI/mL, blank LNC:
93 UI/mL, healthy rats: 98 UI/mL) and at D90 for ALT levels
(LNC
188Re-SSS – 80 MBq: 78 UI/mL, sham group: 66 UI/mL,
188ReO4
- group: 78 UI/mL, blank LNC: 76 UI/mL, healthy rats:
87 UI/mL). On the other side, hepatotoxicity was highlighted
after a single injection of 120 MBq of LNC
188Re-SSS with ALT
and AST levels higher in comparison with control groups at D12
(AST, LNC
188Re-SSS – 120 MBq group: 151 UI/mL; ALT,
LNC
188Re-SSS – 120 MBq group: 146 UI/mL) up to D105
(AST, LNC
188Re-SSS – 120 MBq group: 129 UI/mL; ALT,
LNC
188Re-SSS – 120 MBq group: 122 UI/mL).
VEGF quantification
Results showed major differences between LNC
188Re-SSS –
80 MBq and the control groups (Figure 4). At D65, the VEGF
concentration was approximately half as high in LNC
188Re-SSS rats
versus each control group (LNC
188Re-SSS – 80 MBq group:
21.27 pg/mL; sham rats: 49.31 pg/mL;
188ReO4
- group: 51.57 pg/
m L ;b l a n kL N Cg r o u p :4 2 . 2 8p g / m L )( p LNC188Re-SSS/sham=0.0083;
pLNC188Re-SSS/blank LNC=0.016; pLNC188Re-SSS/188ReO4-=0.0008).
This remains lower up to D80 (LNC
188Re-SSS – 80 MBq group:
69 pg/mL; sham rats: 131.50 pg/mL;
188ReO4
- group: 108.7 pg/
mL; blank LNC group: 91.21 pg/mL) (pLNC188Re-SSS/sham=
0.043; pLNC188Re-SSS/blank LNC=0.0188; pLNC188Re-SSS/188ReO4-=
0.0023).
Table 2. Descriptive and statistical data from the survival study.
Median
survival
time
(days) IMST (%)
Max
survival
time
(days)
Min
survival
time
(days)
Long-term
survivors
p values
versus
sham
p values
versus
blank
LNC
p values
versus
188ReO4
-
p values
versus
LNC188Re-
SSS
80 MBq
p values
versus
LNC188Re-SSS
120 MBq
Sham
188ReO4
- Sham
188ReO4
-
LNC
188Re-SSS -
80 MBq (n=12)
118627 54 107 154 72 1 7 0.0139* 0.0118
£ 0.0102
$ - 0.4431
LNC
188Re-SSS -
120 MBq (n=11)
97618 26 70 140 74 0 2 0.0367 0.0236
£ 0.0219
$ 0.4431 -
Sham (n=12) 77619 6 34 105 49 0 0 - 0.2440 0.4247 0.0139
1 0.0367
Blank LNC (n=7) 51619 -34 211 92 38 0 0 0.0749 - 0.7237 0.0118
1 0.0236
#
188ReO4
-(n=4) 57624 226 - 90 41 0 0 0.4247 0.7237 - 0.0102
1 0.0219
#
The increase in the median survival time (IMST%) is calculated in comparison to the sham and the
188Re-perrhenate groups. Comparisons of survival data using the log-
rank test (Mantel-Cox test) versus sham group (*p,0.05), blank LNC (
£p,0.05),
188Re04
- group (
$p,0.05), LNC
188Re-SSS – 80 MBq (
1p,0.05), LNC
188Re-SSS – 120 MBq
(
#p,0.05).
doi:10.1371/journal.pone.0016926.t002
Figure 1. TEP images after the catheterization of the hepatic artery and tissue distributions. a: A, B, and C: TEP images after 1.5 h, 3 h,
and 24 h of the
188Re-perrhenate solution; D, E, and F: TEP images after 1.5 h, 3 h, and 24 h of the LNC
188Re-SSS solution b: Organ biodistribution of
188ReO4
- (n=12) and LNC
188Re-SSS (n=12) solutions 1.5 h, 3 h, and 24 h following the intra-hepatic injection. Results are expressed as a percent of
injected dose per gram of organ, mean 6 SD.
doi:10.1371/journal.pone.0016926.g001
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188Re-SSS rats, respectively;
T2-weighted images of control rats (C) and LNC
188Re-SSS (D) at D100 after the end of tumor induction. Tumors appear as hypersignals (i arrows);
healthy liver (ii arrow).
doi:10.1371/journal.pone.0016926.g003
Figure 2. Kaplan-Meier survival curves of rats with induced HCC. On D10, rats were treated with 80 MBq (n=12) and 120 MBq (n=11) of
LNC
188Re-SSS, sham rats (n=12), blank LNC (n=8) and 80 MBq of
188Re-perrhenate solution (n=4).
doi:10.1371/journal.pone.0016926.g002
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The use of LNCs, with a structure similar to lipoproteins, could
represent a promising therapeutic modality for HCC manage-
ment, as they modify the biodistribution of entrapped therapeutic
agents [12,13,14]. These nano-objects include only FDA-approved
excipients and are composed of a lipidic core leading to the
entrapment of lipophilic molecules such as
188Re-SSS [12],
surrounded by a tension-active shell which induce physico-
chemical properties different from those of the drug. Additionally,
their nanometric scale (LNC
188Re-SSS mean diameter: 50 nm),
and their low polydispersity index but also, the reduced viscosity of
the drug, represent real advantages. It could likely avoid the
excessive embolization process observed with chemoembolization
(DC-beads
TM – mean diameter: 300–500 mm [15]) and may
penetrate more deeply inside the tumor blood vessels in
comparison with
90Y-microspheres devices (mean diameter
around: 20–40 mm).
The first step in this study was to demonstrate the relevance of
the encapsulation of Rhenium-188 for selective internal radio-
therapy on a HCC rat model. The observed liver uptake following
LNC
188Re-SSS injection and
188Re-perrhenate accumulation in
the stomach, which have been already reported in the literature
[13,14], validate the interest of the encapsulation of Rhenium-188.
Organ biodistribution results indicated that LNC
188Re-SSS
clearance from the blood was mainly ascribed to the liver. The
enhancement permeability retention effect (EPR) may account for
these findings [6]. This phenomenon could be explained by the
size of LNC
188Re-SSS but Ku ¨pffer cells could be another
explanation for these observations. In fact, it has been
demonstrated that Ku ¨pffer cells and some macrophages are
involved in nanoparticle capture [16]. Thus, the physico-
chemical properties of particulate systems improve the liver
uptake of Rhenium-188.
The internal radiotherapy study by intra-arterial injection of
LNC
188Re-SSS was carried out on a chemically induced (DENA)
HCC rat model. 100% tumor take was observed, with a median
survival time ranging from 51 to 77 days after the end of tumor.
Three control groups were performed:
188Re-perrhenate, blank
LNC and sham groups. Neither the injection of the
188Re-
perrhenate solution nor the injection of blank LNC significantly
modified rat survival, as the median survival time was 58 and 51
days respectively. The median survival time of the sham group (77
days) was higher than that of the
188Re-perrhenate and blank LNC
groups. This could be explained by a less invasive surgery, as
neither hepatic artery catheterization nor injection, which could
modify the hemodynamic parameters, were performed. As a
consequence, treated groups (LNC
188Re-SSS – 80 MBq;
LNC
188Re-SSS – 120 MBq) were compared with both
188Re-
perrhenate or blank LNC groups and sham group.
The LNC
188Re-SSS – 80 MBq treatment was the most effective
with 7/12 or 2/12 rats being long-term survivors and an IMST
ranging from 107% to 54% according to the control group (
188Re-
perrhenate groups or sham, respectively). These results correlated
Table 3. AST kinetics.
AST UI/mL
LNC
188Re-SSSS
Group 1
(80 MBq; n=12)
p values vs Group 6
LNC
188Re-SSSS
Group 2
(120 MBq; n=11)
p values vs Group 6
Sham
Group 3
n=12
p values vs Group 6
188ReO4
-
Group 4
n=4
p values vs Group 6
Blank LNC
Group 5
n=10
p values vs Group 6
Healthy rats
Group 6
n=10
-
d12 10467.26
0.421*
15169.48
0.0283*
74619.8
0.2547
87611.31
0.1292
84611.67
0.1361
76611.78
-
d18 9768.12
0.0489*
147614.62
0.0193*
77616.32
0.3415
9769.73
0.0418*
7869.56
0.3190
8269.45
-
d25 102610.76
0.0374*
143610.78
0.0342
88612.78
0.2172
92610.72
0.0426*
95615.74
0.0435*
79610.32
-
d30 114611.85
0.0372*
140615.04
0.0187*
85618.59
0.7341
9668.43
0.3517
106622.16
0.1214
89613.57
-
d45 109612.64
0.464*
12963.11
0.0231*
105620.1
0.1322
110611.87
0.1212
108625.9
0.1189
9769.74
-
d55 80620.36
0.4522
12766.8
0.0251*
95616.62
0.3781
106619.95
0.1429
93611.43
0.5123
98612.78
-
d65 8467.14
0.5631
12664.89
0.0467
82614.85
0.5515
95612.38
0.4287
85614.75
0.5744
109621.32
-
d80 87610.89
0.1865
128619.99
0.0359*
92613.67
0.1432
88610.24
0.3428
97617.59
0.4682
89610.38
-
d90 7765.92
0.5349
13168.83
0.0321*
137640.12
0.0287*
8468.56
0.4864
7967.64
0.5276
9464.66
-
d105 84630.81
0.4326
129610.65
0.0211*
188685.87
0.0083**
-
-
-
-
103623.61
-
d130 9169.79
0.1218
136614.32
0.0107
-
-
-
-
-
-
8568.4
-
d152 159657.98
0.0066**
-
-
-
-
-
-
-
-
76627.40
-
The determination of the AST content in plasma samples for LNC
188Re-SSS (80 MBq and 120 MBq groups), sham,
188ReO4
-, and blank LNC groups at D12, D18, D24, D25,
D30, D45, D55, D65, D80, D90, D105, D130, and D152 after the end of tumor induction. Results are expressed in IU/mL of AST, mean 6 SD. Comparisons of AST content
versus healthy rats (*p,0.05; **p,0.01).
doi:10.1371/journal.pone.0016926.t003
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slowdown in tumor progression in the LNC
188Re-SSS –
80 MBq group.
Increasing the absorded dose to the liver has shown no interest
in terms of survival efficacy as LNC
188Re-SSS – 120 MBq group
gave rise to the worse increase in median survival (IMST%
ranging from 26% to 70% according to the control group).
Hepatotoxicity demonstrated by higher levels of transaminases,
could explain its less efficiency in term of survival.
Angiogenesis plays a key role in the pathogenesis of many cancers
[17]. HCC, a hypervascular tumor, is mainly supplied by hepatic
artery,whereas normal liver parenchymaand dysplastic nodules are
largely supplied by the portal vein [18]. HCCs have been shown to
express many angiogenic factors including VEGF [19]. Moreover,
VEGF expression by the tumor and VEGF levels in patients’ blood
have been shown to correlate with the size, invasiveness, metastases,
and prognosis of HCC [20]. As a consequence, the assessment of
VEGF concentrations in plasma samples was carried out in each
group except for LNC
188Re-SSS – 120 MBq group, which
demonstrated worse results in terms of survival and hepatotoxicity.
The lower VEGF levels, in LNC
188Re-SSS – 80 MBq group in
comparison with control groups, could reflected an altered
angiogenesis in the rat HCC model, which could reduced tumor
progression confirmed by MRI.
Our results pointed out the advantage in using lipid nanocap-
sules, a drug delivery system for SIRT. In that field, an important
breakthrough for HCC treatment has been done, with drug
eluting beads (DEB, DC-beads
TM),
90Y-microspheres (TheraS-
phereH, SIR-SphereH),
188Re-microspheres and nanocarriers.
Dhanasekaran et al. demonstrated that doxorubicin DEB therapy
with unresectable HCC provides a survival advantage over
treatment with conventional chemoembolization [21]. However,
micrometric size of DC-beads (300 to 500 mm) could generate
excessive embolisation leading to Post-Embolization Syndrome
(PES) [22]. Meanwhile DC-beads, SIRT with
90Y-microspheres is
another palliative HCC treatment option, with up to 50% in
tumor HCC size reduction [23,24,25,26].
188Re-microspheres
were also developed for HCC treatment with decrease in tumor
growth after
188Re-microsphere injection [27,28].
Nanocarriers [29,30] enable to load chemotherapeutic agents
such as docetaxel [31] or oligonucleotides [32] were developed in
order to reduce PES observed with DC-beads. Results demon-
strated a slowdown in tumor progression but most of these
preclinical studies assessed their efficacy on a subcutaneous HCC
model.
We have developed 50 nm-lipid nanocapsules loaded with
Rhenium-188 for selective internal radiotherapy and have assessed
their efficiency on a chemically induced HCC rat model, known for
its physiological properties similar to human hepatocarcinoma. Due
to their nanometric scale, no embolisation process was possible.
This could represent a real advantage as tumoral hypoxia areas
could be reduced allowing a better efficiency of ionizing radiations.
Table 4. ALT Kinetics.
ALT UI/mL
LNC
188Re-SSSS
Group 1
(80 MBq; n=12)
p values vs Group 6
LNC
188Re-SSSS
Group 2
(120 MBq; n=11)
p values vs Group 6
Sham
Group 3
n=12
p values vs Group 6
188ReO4
-
Group 4
n=4
p values vs Group 6
Blank LNC
Group 5
n=10
p values vs Group 6
Healthy rats
Group 6
n=10
-
d12 9568.72
0.0392*
14669.78
0.0083**
64610.01
0.1281
8368.48
0.1042
7469.12
0.2148
67612.14
-
d18 101613.62
0.0261*
148612.64
0.0021**
7369.41
0.0021**
7467.62
0.1118
68612.56
0.3512
7267.65
-
d25 98610.37
0.0437*
141610.56
0.0092**
83613.67
0.3163
69611.74
0.0912
82610.86
0.1006
87610.29
-
d30 87614.67
0.1872
134612.76
0.0017**
79610.98
0.4113
8468.94
0.2275
7969.67
0.3127
7668.34
-
d45 99614.14
0.0439*
12866.78
0.0376*
83622.05
0.1024
93611.57
0.3510
95620.11
0.3121
86611.33
-
d55 88612.63
0.1132
133613.95
0.0051**
7666.51
0.2941
6767.84
0.2230
7767.12
0.1949
8069.52
-
d65 90615.65
0.0734
126612.56
0.0421*
7968.94
0.4376
7265.78
0.3311
8169.53
0.2414
84614.48
-
d80 73612.84
0.5635
125624.29
0.0034**
7267.36
0.2037
8469.23
0.1882
92615.67
0.0613
7967.48
-
d90 7860.74
0.4523
129610.85
0.0288*
6669.95
0.4579
78610.45
0.1776
7666.89
0.2430
87615.03
-
d105 86624.74
0.2649
122611.43
0.0107*
120614.81
0.0119*
-
-
-
-
7765.02
-
d130 74611.65
0.3498
13969.52
0.0034**
-
-
-
-
-
-
69610.61
-
d152 123627.98
0.0056**
-
-
-
-
-
-
-
-
73612.59
-
The determination of the ALT content in plasma samples for LNC
188Re-SSS (80 MBq and 120 MBq groups), sham,
188ReO4
-, and blank LNC groups at D12, D18, D24, D25,
D30, D45, D55, D65, D80, D90, D105, D130, and D152 after the end of tumor induction. Results are expressed in IU/mL of AST, mean 6 SD. Comparisons of ALT content
versus healthy rats (*p,0.05; **p,0.01).
doi:10.1371/journal.pone.0016926.t004
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been shown to prolong the median survival time by 3 months in
patients with advanced HCC [33]. As LNC
188Re-SSS seems to
alter angiogenic process, their combination with sorafenib as an
adjuvant therapy could be a valuable approach in the treatment of
advanced HCC.
In conclusion,
188Re-loaded LNCs appear to be an encouraging
new radiopharmaceutical carrier for HCC internal radiotherapy
which could penetrate more deeply inside the tumor blood vessels.
A comparative study of LNC
188Re-SSS and
90Y-microspheres
SIRT, already used in clinical application, will probably provide
informations of the effect of the size of particle systems and also in
term of dosimetry.
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